Symbol over Substance
By Jesse Reynolds,
GeneWatch (Sep-Oct 2009)
| 10. 22. 2009
Despite over a decade of hype, cloning-based stem cell research has offered little in the way of scientific progress. It has been more symbol than substance; more moving target than realistic goal. However, by complicating both politics and policy, is has been a monkey wrench in the gears for progressive advocates of responsible biotechnologies.
Although there had been previous technological and policy developments in reproductive cloning, the 1996 birth of Dolly the Sheep - the first cloned mammal - catalyzed widespread concern and numerous laws about human reproductive cloning throughout the world. It quickly became clear that, outside of a handful of extreme techno-enthusiasts, reproductive human cloning had few defenders. Prohibitions in every nation, and even internationally, seemed to be just around the corner.
But two years after Dolly's birth, scientists led by James Thomson at the University of Wisconsin isolated human embryonic stem cells. These cells' power to differentiate into any tissue type - a characteristic called pluripotency - represented the foundation of a potential new type of medicine, in which cellular therapies could be used to repair the...
Related Articles
By Emily Mullin, Wired | 04.23.2026
A STARTUP OUT of Utah, Paterna Biosciences, says it has successfully grown functional human sperm in a lab and used the sperm to make visibly healthy-looking embryos. The technique could eventually help men with certain types of infertility have biological children...
By Peter Ward, Slate | 03.30.2026
I’m in a cramped examination room at a clinic in Panama City. The lights are dim, and calming classical music plays from built-in speakers. A nurse has injected a dose of stem cells into Kenneth Scott through an IV in...
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
By Emily Mullin, Wired | 03.23.2026
As the Trump administration phases out the use of animal experimentation across the federal government, a biotech startup has a bold idea for an alternative to animal testing: nonsentient “organ sacks.”
Bay Area-based R3 Bio has been quietly pitching the...